newsA preliminary Phase 2 clinical trial has demonstrated that patients…
26 February 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A preliminary Phase 2 clinical trial has demonstrated that patients with acute ischemic stroke, can safely tolerate high doses of 3K3A-APC, a promising anti-stroke drug...